Michael Entzeroth
Directeur des opérations chez Cennerv Pharmaceuticals Ltd.
Profil
Michael Entzeroth is currently the Chief Operating & Scientific Officer at Cennerv Pharmaceuticals Ltd.
He previously worked as the Deputy Director-Global Alliances at the Agency for Science, Technology & Research from 2007 to 2013, and as the Managing Director at Pharma Resources Asia Pte Ltd.
from 2006 to 2014.
He also served as the Vice President-New Technologies at Eurofins-Cerep SA from 1999 to 2002, and as the Head-Research Laboratory at Boehringer Ingelheim Pharma GmbH & Co., KG from 1985 to 1995.
Additionally, he briefly worked as the Chief Scientific Officer at S*BIO Pte Ltd.
and Chakra Biotech Pte Ltd.
Dr. Entzeroth received his undergraduate and doctorate degrees from Universität zu Köln in 1980 and 1983, respectively.
Postes actifs de Michael Entzeroth
| Sociétés | Poste | Début |
|---|---|---|
Cennerv Pharmaceuticals Ltd.
 Cennerv Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cennerv Pharmaceuticals Ltd. engages in the pharmaceutical development specializing in CNS disorders with an initial focus on mental health such as depression, insomnia, dementia, schizophrenia and autism. The company was founded on July 13, 2015 and is headquartered in Singapore. | Directeur des opérations | - |
Anciens postes connus de Michael Entzeroth
| Sociétés | Poste | Fin |
|---|---|---|
| Pharma Resources Asia Pte Ltd. | Directeur Général | 01/12/2014 |
| Chakra Biotech Pte Ltd. | Directeur Technique/Scientifique/R&D | 01/12/2014 |
Agency for Science, Technology & Research
 Agency for Science, Technology & Research Miscellaneous Commercial ServicesCommercial Services Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore. | Corporate Officer/Principal | 01/07/2013 |
| EUROFINS CEREP | Corporate Officer/Principal | 01/09/2002 |
Boehringer Ingelheim Pharma GmbH & Co., KG
 Boehringer Ingelheim Pharma GmbH & Co., KG BiotechnologyHealth Technology Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Ingelheim, Germany. The German company was founded in 1885. The CEO is Sabine Nikolaus. | Corporate Officer/Principal | 01/02/1995 |
Formation de Michael Entzeroth
| Universität zu Köln | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EUROFINS CEREP | Commercial Services |
| Entreprise privées | 6 |
|---|---|
Agency for Science, Technology & Research
Agency for Science, Technology & Research Miscellaneous Commercial ServicesCommercial Services Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore. | Commercial Services |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Health Technology |
Boehringer Ingelheim Pharma GmbH & Co., KG
Boehringer Ingelheim Pharma GmbH & Co., KG BiotechnologyHealth Technology Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Ingelheim, Germany. The German company was founded in 1885. The CEO is Sabine Nikolaus. | Health Technology |
| Chakra Biotech Pte Ltd. | |
Cennerv Pharmaceuticals Ltd.
Cennerv Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cennerv Pharmaceuticals Ltd. engages in the pharmaceutical development specializing in CNS disorders with an initial focus on mental health such as depression, insomnia, dementia, schizophrenia and autism. The company was founded on July 13, 2015 and is headquartered in Singapore. | Health Technology |
| Pharma Resources Asia Pte Ltd. |
